Cargando…
The use of a neuromuscular blocking agent could significantly decrease mortality in moderate-to-severe ARDS patients: is moderate ARDS the best indication for neuromuscular blocking agents
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218617/ https://www.ncbi.nlm.nih.gov/pubmed/32404187 http://dx.doi.org/10.1186/s13054-020-02947-x |
| _version_ | 1783532836819566592 |
|---|---|
| author | Honore, Patrick M. Mugisha, Aude Kugener, Luc Redant, Sebastien Attou, Rachid Gallerani, Andrea De Bels, David |
| author_facet | Honore, Patrick M. Mugisha, Aude Kugener, Luc Redant, Sebastien Attou, Rachid Gallerani, Andrea De Bels, David |
| author_sort | Honore, Patrick M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7218617 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72186172020-05-20 The use of a neuromuscular blocking agent could significantly decrease mortality in moderate-to-severe ARDS patients: is moderate ARDS the best indication for neuromuscular blocking agents Honore, Patrick M. Mugisha, Aude Kugener, Luc Redant, Sebastien Attou, Rachid Gallerani, Andrea De Bels, David Crit Care Letter BioMed Central 2020-05-13 /pmc/articles/PMC7218617/ /pubmed/32404187 http://dx.doi.org/10.1186/s13054-020-02947-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Letter Honore, Patrick M. Mugisha, Aude Kugener, Luc Redant, Sebastien Attou, Rachid Gallerani, Andrea De Bels, David The use of a neuromuscular blocking agent could significantly decrease mortality in moderate-to-severe ARDS patients: is moderate ARDS the best indication for neuromuscular blocking agents |
| title | The use of a neuromuscular blocking agent could significantly decrease mortality in moderate-to-severe ARDS patients: is moderate ARDS the best indication for neuromuscular blocking agents |
| title_full | The use of a neuromuscular blocking agent could significantly decrease mortality in moderate-to-severe ARDS patients: is moderate ARDS the best indication for neuromuscular blocking agents |
| title_fullStr | The use of a neuromuscular blocking agent could significantly decrease mortality in moderate-to-severe ARDS patients: is moderate ARDS the best indication for neuromuscular blocking agents |
| title_full_unstemmed | The use of a neuromuscular blocking agent could significantly decrease mortality in moderate-to-severe ARDS patients: is moderate ARDS the best indication for neuromuscular blocking agents |
| title_short | The use of a neuromuscular blocking agent could significantly decrease mortality in moderate-to-severe ARDS patients: is moderate ARDS the best indication for neuromuscular blocking agents |
| title_sort | use of a neuromuscular blocking agent could significantly decrease mortality in moderate-to-severe ards patients: is moderate ards the best indication for neuromuscular blocking agents |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218617/ https://www.ncbi.nlm.nih.gov/pubmed/32404187 http://dx.doi.org/10.1186/s13054-020-02947-x |
| work_keys_str_mv | AT honorepatrickm theuseofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT mugishaaude theuseofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT kugenerluc theuseofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT redantsebastien theuseofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT attourachid theuseofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT galleraniandrea theuseofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT debelsdavid theuseofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT honorepatrickm useofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT mugishaaude useofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT kugenerluc useofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT redantsebastien useofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT attourachid useofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT galleraniandrea useofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents AT debelsdavid useofaneuromuscularblockingagentcouldsignificantlydecreasemortalityinmoderatetosevereardspatientsismoderateardsthebestindicationforneuromuscularblockingagents |